Skip to main content

HLA-A KO cell line available to order. KO validated by Next Generation Sequencing, Western blot. Free of charge wild type control provided. Knockout achieved by CRISPR/Cas9 X = 17 bp deletion Frameshift = 99.8%.

Be the first to review this product! Submit a review

Images

Western blot - Human HLA-A knockout A-431 cell line (AB261894), expandable thumbnail
  • Western blot - Human HLA-A knockout A-431 cell line (AB261894), expandable thumbnail
  • Next Generation Sequencing - Human HLA-A knockout A-431 cell line (AB261894), expandable thumbnail

Key facts

Cell type
A-431
Species or organism
Human
Tissue
Skin
Form
Liquid
Knockout validation
Next Generation Sequencing, Western blot
Mutation description
Knockout achieved by CRISPR/Cas9 X = 17 bp deletion Frameshift = 99.8%

Alternative names

Antigen Presenting Molecule, HLA class I histocompatibility antigen, A 1 alpha chain, Leukocyte antigen class I A, MHC class I antigen HLA A heavy chain, Major histocompatibility complex, class I, A

Recommended products

HLA-A KO cell line available to order. KO validated by Next Generation Sequencing, Western blot. Free of charge wild type control provided. Knockout achieved by CRISPR/Cas9 X = 17 bp deletion Frameshift = 99.8%.

Key facts

Cell type
A-431
Form
Liquid
Mutation description
Knockout achieved by CRISPR/Cas9 X = 17 bp deletion Frameshift = 99.8%
Disease
Epidermoid Carcinoma
Concentration
Loading...

Properties

Gene name
HLA-A
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Next Generation Sequencing, Western blot

Quality control

STR analysis
CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level
EU: 1 US: 1
Adherent/suspension
Adherent
Gender
Female

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium
DMEM (High Glucose) + 10% FBS
Cryopreservation medium
Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Storage

Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Notes

Recommended control: Human wild-type A-431 cell line (ab263975). Please note a wild-type cell line is not automatically included with a knockout cell line order, if required please add recommended wild-type cell line at no additional cost using the code WILDTYPE-TMTK1.

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.

Supplementary info

This supplementary information is collated from multiple sources and compiled automatically.
Activity summary

HLA-A also known as Human Leukocyte Antigen A is a protein that is part of the major histocompatibility complex (MHC) class I molecules. It has an approximate molecular mass of 44 kDa. HLA-A is expressed on the surface of nearly all nucleated cells and interacts with CD8+ T lymphocytes. Known for its role in immune recognition HLA-A presents endogenous peptide antigens to the T-cell receptor on cytotoxic T cells initiating immune responses to eliminate infected or malignant cells.

Biological function summary

This target functions as a component of the MHC class I molecule complex. HLA-A binds peptides derived from proteasomal degradation of intracellular proteins and presents these peptides on the cell surface. The function plays an essential role in immune surveillance and distinction between self and non-self. This antigen presentation is important for immune responses against viral infections and tumor surveillance influencing the activation and proliferation of T lymphocytes.

Pathways

HLA-A plays a significant role in the antigen processing and presentation pathway. It is closely related to the TAP (Transporter associated with Antigen Processing) proteins which transport antigenic peptides into the endoplasmic reticulum for loading onto MHC class I molecules. Additionally the target interacts with the CD8 molecule on cytotoxic T cells. This interaction is important within the immune response pathway contributing to the recognition and destruction of infected cells.

Associated diseases and disorders

HLA-A has been associated with autoimmune diseases and transplant rejection. It plays a significant role in conditions like ankylosing spondylitis where specific HLA-A subtypes contribute to disease susceptibility. Additionally mismatches in HLA-A typing can lead to transplant rejection. In such scenarios anti-HLA antibodies can develop causing damage to transplant tissues. The complex interaction of HLA-A with related proteins such as other MHC class I molecules influences immune response outcomes in these diseases.

Product promise

We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.

In the unlikely event of one of our products not working as expected, you are covered by our product promise.

Full details and terms and conditions can be found here:
Terms & Conditions.

3 product images

Downloads

Product protocols

For this product, it's our understanding that no specific protocols are required. You can:

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com